Literature DB >> 11216636

Large and asymptomatic pancreatic islet cell tumor in a patient with multiple endocrine neoplasia type 1.

M Sato1, M Kihara, A Nishitani, K Murao, S Kobayashi, A Miyauchi, J Takahara.   

Abstract

The major phenotypes of multiple endocrine neoplasia type 1 (MEN 1) consist of three lesions characterized by hyperparathyroidism, pituitary tumors, and endocrine pancreatic tumors. The endocrine pancreatic tumors are a significant cause of disease-related mortality in MEN 1. Although symptomatic pancreatic tumors such as insulinoma and gastrinoma should be resected, the management of asymptomatic pancreatic tumors is not established. In asymptomatic pancreatic tumors, the most important factor is the propensity for malignant transformation of the tumors. Although there are no means to foresee it, the size of the pancreatic tumors might be predictive of malignant development in MEN 1. We report here a patient with MEN 1 who had a large asymptomatic pancreatic tumor. The patient (72-yr-old man) was diagnosed with primary hyperparathyroidism and underwent a total parathyroidectomy. Genetic examination showed a germline mutation of the MEN1 gene (E45G). Abdominal magnetic resonance imaging revealed a large (>6 cm) tumor with a heterogeneous pattern in the tail of the pancreas. No metastases of the tumor were evident. Serum levels of insulin, gastrin, and glucagon were normal, and the patient had no symptoms. Operative resection was performed, and microscopic examination revealed that the tumor was an islet cell tumor stained with multiple hormones. This is a case indicating that asymptomatic pancreatic tumors associated with MEN 1 might be indolent independent of their size.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11216636     DOI: 10.1385/ENDO:13:3:263

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  17 in total

1.  Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE).

Authors:  G Cadiot; A Vuagnat; I Doukhan; A Murat; G Bonnaud; B Delemer; G Thiéfin; A Beckers; M Veyrac; C Proye; P Ruszniewski; M Mignon
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682

2.  Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands.

Authors:  H F Vasen; C B Lamers; C J Lips
Journal:  Arch Intern Med       Date:  1989-12

3.  Positional cloning of the gene for multiple endocrine neoplasia-type 1.

Authors:  S C Chandrasekharappa; S C Guru; P Manickam; S E Olufemi; F S Collins; M R Emmert-Buck; L V Debelenko; Z Zhuang; I A Lubensky; L A Liotta; J S Crabtree; Y Wang; B A Roe; J Weisemann; M S Boguski; S K Agarwal; M B Kester; Y S Kim; C Heppner; Q Dong; A M Spiegel; A L Burns; S J Marx
Journal:  Science       Date:  1997-04-18       Impact factor: 47.728

4.  The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized?

Authors:  J J Shepherd
Journal:  Arch Surg       Date:  1991-08

5.  Plasma chromogranin A in patients with multiple endocrine neoplasia type 1.

Authors:  D Granberg; M Stridsberg; R Seensalu; B Eriksson; G Lundqvist; K Oberg; B Skogseid
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

Review 6.  Multiple endocrine neoplasia type 1 (MEN-1). Clinical, biochemical and genetical investigations.

Authors:  K Oberg; B Skogseid; B Eriksson
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

7.  Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription.

Authors:  S K Agarwal; S C Guru; C Heppner; M R Erdos; R M Collins; S Y Park; S Saggar; S C Chandrasekharappa; F S Collins; A M Spiegel; S J Marx; A L Burns
Journal:  Cell       Date:  1999-01-08       Impact factor: 41.582

8.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

9.  A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience.

Authors:  B Skogseid; K Oberg; L Benson; P G Lindgren; L E Lörelius; G Lundquist; L Wide; E Wilander
Journal:  J Clin Endocrinol Metab       Date:  1987-06       Impact factor: 5.958

10.  Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size.

Authors:  J K Lowney; M M Frisella; T C Lairmore; G M Doherty
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

View more
  2 in total

Review 1.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

2.  Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Authors:  David C Metz; Guillaume Cadiot; Pierre Poitras; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2017-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.